1. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG
- Author
-
Karen Chau, Michael S. Binkley, Chang Ok Suh, Carla Hajj, Berthe M.P. Aleman, Scott V. Bratman, Sara Hardy, Masahiko Oguchi, Andrea K. Ng, Youlia M. Kirova, Bouthaina S. Dabaja, David C. Hodgson, Andrea Riccardo Filippi, Monica Chelius, Tarec Christoffer El-Galaly, Gabriele Reinartz, Mario Levis, Anders Krog Vistisen, Michael P. Mac Manus, Jessica L. Brady, Alex Balogh, Richard T. Hoppe, Hans Theodor Eich, Louis S. Constine, Andrew Wirth, Joachim Yahalom, Michael P. Jones, T.Y. Andraos, Seo Hee Choi, N. George Mikhaeel, and Umberto Ricardi
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Follicular lymphoma ,Lymphoma, Follicular/diagnostic imaging ,Biochemistry ,Neoplasm Recurrence, Local/diagnostic imaging ,Young Adult ,Fluorodeoxyglucose F18 ,medicine ,Humans ,Positron Emission Tomography Computed Tomography/standards ,Survival rate ,Aged ,Retrospective Studies ,Aged, 80 and over ,Radiotherapy/mortality ,medicine.diagnostic_test ,Surrogate endpoint ,business.industry ,Hazard ratio ,Retrospective cohort study ,Cell Biology ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,Radiation therapy ,Positron emission tomography ,Female ,Radiology ,Fresh frozen plasma ,Radiopharmaceuticals ,business ,Follow-Up Studies - Abstract
Radiotherapy (RT) can be curative in patients with localized follicular lymphoma (FL), with historical series showing a 10-year disease-free survival of 40 to 50%. As 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography with computerized tomography (PET-CT) upstages 10 to 60% of patients compared to CT, we sought to evaluate outcomes in patients staged by PET-CT, to determine if more accurate staging leads to better patient selection and results. We conducted a multicenter retrospective study under the direction of the International Lymphoma Radiation Oncology Group (ILROG). Inclusion criteria were: RT alone for untreated stage I to II FL (grade 1-3A) with dose equivalent ≥24 Gy, staged by PET-CT, age ≥18 years, and follow-up ≥3 months. End points were freedom from progression (FFP), local control, and overall survival (OS). A total of 512 patients treated between 2000 and 2017 at 16 centers were eligible for analysis; median age was 58 years (range, 20-90); 410 patients (80.1%) had stage I disease; median RT dose was 30 Gy (24-52); and median follow-up was 52 months (3.2-174.6). Five-year FFP and OS were 68.9% and 96%. For stage I, FFP was 74.1% vs 49.1% for stage II (P < .0001). Eight patients relapsed in-field (1.6%). Four had marginal recurrences (0.8%) resulting in local control rate of 97.6%. On multivariable analysis, stage II (hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.44-3.10) and BCL2 expression (HR, 1.62; 95% CI, 1.07-2.47) were significantly associated with less favorable FFP. Outcome after RT in PET-CT staged patients appears to be better than in earlier series, particularly in stage I disease, suggesting that the curative potential of RT for truly localized FL has been underestimated.
- Published
- 2019
- Full Text
- View/download PDF